Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02478424|
Recruitment Status : Unknown
Verified June 2015 by Rabin Medical Center.
Recruitment status was: Not yet recruiting
First Posted : June 23, 2015
Last Update Posted : June 23, 2015
Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa possesses potent anti-inflammatory and immunosuppressive properties. In a recent prospective phase II study (NCT01385124) 48 consecutive adult patients undergoing allogeneic hematopoietic cell transplantation were given CBD 300 mg/day starting 7 days before transplantation until day 30, on top of standard GVHD prophylaxis consisting of cyclosporine and a short course of methotrexate. There were no grade 3-4 toxicities attributed to CBD. None of the patients developed acute GVHD while consuming CBD. With a median follow-up of 16 months, the cumulative incidence rates of grade 2-4 and grade 3-4 acute GVHD by day 100 were 12.1% and 5%, respectively. Compared to 101 historical control subjects given standard GVHD prophylaxis, the hazard ratio of developing grade 2-4 acute GVHD among subjects treated with CBD plus standard GVHD prophylaxis was 0.3 (p=0.0002). Among patients surviving more than 100 days, the cumulative incidence of moderate-to-severe chronic GVHD at 12 and 18 months were 20% and 33%, respectively.
The aim of this study is to explore the safety and efficacy of extended use of CBD until day 100 in the prevention of acute and chronic GVHD.
|Condition or disease||Intervention/treatment||Phase|
|Graft vs Host Disease||Drug: Cannabidiol Drug: cyclosporine Drug: Methotrexate||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Extended Use of Cannabidiol for the Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation|
|Study Start Date :||July 2015|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||June 2017|
Experimental: Cannabidiol arm
Patients undergoing an allogeneic hematopoietic cell transplantation will be given standard GVHD prophylaxis comprising cyclosporine and a short course of methotrexate plus CBD 150 mg BID starting 7 days before transplantation until day 100.
Patients will receive standard GVHD prophylaxis consisting of cyclosporine A twice daily starting on day -1 with target trough levels of 200-400 ng/mL and a short course of methotrexate (15 mg/ m2 on day 1 and 10 mg/ m2 on days days 3 and 6). Patients transplanted from unrelated donors will receive ATG Fresenius at a low dose of 5 mg/kg on days -3 to -1.
Patients will be given oral CBD 150 mg BID starting 7 days before transplantation until day 100.
Other Name: CBD
- Incidence of grade 2-4 and grade 3-4 acute GVHD by day 100 [ Time Frame: 100 days ]
- grade 3-4 adverse effects attributed to CBD consumption [ Time Frame: 180 days ]
- Incidence of overall chronic GVHD and moderate to severe chronic GVHD by 12 months [ Time Frame: 12 months ]
- Incidence of late onset acute GVHD [ Time Frame: 12 months ]
- Non relapse mortality [ Time Frame: 12 months ]
- Relapse rate [ Time Frame: 12 months ]
- Overall survival [ Time Frame: 12 months ]
- Adherence to study protocol [ Time Frame: Until day 100 ]Percentage of doses actually taken as reported by patients
- Disease free and immunosuppression free survival by 12 months [ Time Frame: 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02478424
|Contact: Moshe Yeshurun, MDemail@example.com|
|Contact: Liat Shargian, MD||972-54-2394930||LIATSHR@clalit.org.il|